Medtronic and Sanofi embark on a global alliance to combine human and financial resources in the interest of new products and services for patients with diabetes.
Sanofi subsidiary Genzyme agrees to pay $22.3 million to settle accusations that its sales rep encouraged off-label use of the Seprafilm surgical product.
Massachusetts-based Genzyme Corp., a subsidiary of Sanofi (NYSE:SNY), agreed to pay $22.3 million to settle a whistleblower lawsuit accusing the company of off-label marketing of its Seprafilm surgical product.
A pair of brokers plead guilty to charges of insider trading in Stryker Corp. stock ahead of its 2011 acquisition of Orthovita.
A pair of brokers pleaded guilty to federal insider trading charges yesterday, admitting that they used tips from a former Stryker (NYSE:SYK) marketing executive to make illicit trades ahead of the medical device company's 2011 acquisition of Orthovita.
Unilife shares are up more than 24% this week on news of a deal with MedImmune, the biologics arm of pharmaceuticals giant AstraZeneca.
Unilife (NSDQ:UNIS) shares are up more than 24% this week on a supply deal for its wearable injectors it inked with MedImmune, the biologics division of pharma giant AstraZeneca (NYSE:AZN).
Unilife CEO Alan Shortall says a pair of Forbes articles were "vindictive," "malicious" and a "slap in the face" to analysts and portfolio managers who put their trust in the company.
French healthcare giant Sanofi is the last buyer still in the running to acquire German Bayer's blood glucose management devices, a deal that may be worth more than $1.5 billion, sources say.
Johnson & Johnson, already the world's largest health products maker, could have its eye on Edwards Lifesciences and St. Jude Medical as potential acquisitions, analysts say.